Shows
BioBusiness.TV, the podcast! ver2ASBMR Review - Part 1: AMGN Makes NewsYou are Watching:
Post ASBMR Review: Amgen's Denosumab Lowers Fracture Risk, Makes the News at the American Society for Bone and Mineral Research (ASBMR) meeting.
Mike is back from a very exciting American Society for Bone and Mineral Research (ASBMR) meeting in Montreal. Amgen made the news with the results of its phase 3 trial for Denosumab. Mike explains Denosumab sets a new standard for a highly efficacious, safe, and convenient treatment for a disease that has a very high unmet need, despite its prevalence. Mike and Jean-Loup comparison Denosumab to Novartis' Reclast and other Bisphosphonates - looking at safety, tolerability...2008-09-1901 minBioBusiness.TV, the podcast! ver2ASBMR Review - Part 2: AMGN StrategyYou are Watching:
Post ASBMR Review: Denosumab to Seize Low Hanging Fruit in Osteoporosis Market, with the Potential to Become 1st Line Treatment. Amgen's Currently Inexpensive Shares to Gain 20 points.
After reviewing the Denosumab data released at the ASBMR meeting, it looks like Amgen's osteoporosis drug will be a 2nd line treatment. With 50% of osteoporosis patients going off their bisphosphonates in their fisrt year, Mike King thinks there is a low hanging fruit there. Mike also thinks the drug's profile could allow it to quickly become a first line treatment. Jean-Loup and Mike look at the market, Amgen's pricing for...2008-09-1910 minBioBusiness.TV, the podcast! ver2ASBMR Review - Part 3: Pfizer, MerckYou are Watching:
Post ASBMR Review: A quick look Pfizer's Fablyn, and Merck Odanacatib.
Mike and Jean-Loup take a quick look at some of the other data released at the American Society for Bone and Mineral Research Meeting in Montreal. They review Pfizer's PEARL study for the drug Fablyn, and Merck's phase 2 Odanacatib.
This interview was conducted at the NASDAQ Marketsite, on September 19th, 2008, in New York City.
Featuring:
* Michael King, Director of Research, Rodman & Renshaw
* Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV
DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS...2008-09-1900 minBioBusiness.TV, the podcast! ver2Vivalis CSO Interview - Embryonic Stem Cell TechnologyYou are Watching:
Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production.
Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions.
This interview was conducted at the...2008-07-1701 min